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Abstract. Programmed cell death ligand 1 (PD‑L1) expressed
in cancer cells interacting with its receptor programmed cell
death 1 (PD‑1) expressed in immune cells represents a regulatory axis linked to the suppression and evasion of host immune
functions. The blockade of PD‑1/PD‑L1 interaction using
monoclonal antibodies has emerged as an effective therapy
for several solid tumors; however, durable response has been
observed in a subset of patients with PD‑L1-positive tumors.
Thus, the understanding of the mechanisms responsible for
the expression of PD‑L1 in tumor cells may help to improve
the response to PD‑L1 blockade therapies. In this study, we
investigated whether resveratrol, a grape-derived stilbenoid
with immunoregulatory activity, modulates the expression
of PD‑L1 in breast and colorectal cancer cells. The surface
expression of PD‑L1 was determined by flow cytometry in
cancer cells treated with resveratrol and/or piceatannol. Each
stilbenoid alone induced PD‑L1 and when used in combination, elicited a synergistic upregulation of PD‑L1 in some
cell lines. The induction of PD‑L1 by the combined use of
stilbenoids was most pronounced in the Cal51 triple-negative
breast cancer (TNBC) and SW620 colon cancer cells. The
observed induction of PD‑L1 was transcriptionally mediated by nuclear factor (NF)-κ B, as shown by NF‑κ B reporter
assays, the nuclear accumulation of the p65 subunit of NF‑κ B,
inhibition by the IKK inhibitor, BMS‑345541, and histone the
modification inhibitors, resminostat, entinostat or anacardic
acid. Combined treatment with resveratrol and piceatannol
also decreased tumor cell survival as indicated by the upregulation of the DNA damaging marker, γH2AX, the cleavage
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of caspase 3, the downregulation of the survival markers,
p38-MAPK/c‑Myc, and G1-to-S cell cycle arrest.
Introduction
Programmed cell death ligand 1 (PD‑L1) is a functional ligand
of programmed cell death 1 (PD‑1) (1). The binding of tumor
cell PD‑L1 to immune T-cell PD‑1 inhibits T-cell activation
and attenuates T-cell-mediated immunosuppression (2-4). This
results in the evasion of host antitumor immunity, potentially
reducing the efficacy of anticancer therapies and resulting in
a poor clinical outcome (2,5,6). To counter the escape from
the host immune surveillance system by tumor cells, blockade
strategies using monoclonal antibodies (mAbs) to prevent
the binding of PD‑L1 to PD‑1 have been developed (7-12).
The clinical efficacy of this approach has been demonstrated in certain cancer types, including melanoma (13-16),
non‑small-cell lung cancer (17-19) and renal carcinoma (20).
Blockade therapy differs from tumoricidal chemotherapy in
that its antitumorigenic effects involve boosting host immunity concomitant with the modulation of the expression/
activity of the repertoire of cytotoxic T-cell and T-regulatory
cells (21-24). Although success in anti‑PD‑1/PD‑L1 therapy
has made it possible to achieve tumor eradication and disease
remission/cure, outstanding challenges remain. Only 31% of
patients with advanced melanoma treated intravenously with
anti‑PD‑1 drugs (nivolumab) have exhibited objective tumor
regression (14). Likewise, the same therapeutic regimen has
shown response rates ranging from 25% in renal cancer (20),
to 19% in non‑squamous non‑small-cell lung cancer (17) and
to 20% in squamous non‑small-cell lung cancer (18), respectively. Moreover, a positive therapeutic response typically
occurs in patients with PD‑L1-positive tumors (13,25).
Since the expression of PD‑L1 in cancer cells may affect the
patient response to immune blockade therapy, it is of interest to
identify agents capable of modulating the expression of PD‑L1.
In this study, we focused on resveratrol, a stilbenoid present
abundantly in red wine, red grape skin and peanuts (26,27).
Interest in resveratrol stems largely from the report in 1997 by
Jang et al, showing that the molecule prevents the development
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of pre-neoplastic lesions in carcinogen-exposed mammary
glands, and the inhibition of initiation and promotion of skin
cancer in a mouse model (28). Since then, numerous studies
have demonstrated its broad‑spectrum beneficial health effects,
including, anti‑inflammatory (29,30) and anticancer activities (26). Several mechanisms (31,32) and target proteins for
the biological and pharmacological activities of resveratrol
have been identified and characterized (33-42). Resveratrol
has also been reported to exert immunomodulatory effects, as
illustrated by the induction of interferon (IFN)-γ expression in
CD8+ T-cells both ex vivo and in vivo (43), and the inhibition
of the proliferation of CD4+ T-cells (43,44). Craveiro et al (45)
recently demonstrated that low-dose resveratrol (20 µM) activates human CD4+ cells and induces DNA damage response,
while high-dose resveratrol (100 µM) induces G1 phase cell
cycle arrest, suggesting that resveratrol may act on host immune
cell types in a dose-dependent manner. The chemopreventive
activity of resveratrol was first demonstrated using skin and
breast cancer models (28), and recent clinical trials support the
use of resveratrol in colorectal cancer (46,47). Thus, in this study,
we selected breast and colorectal cancer cell lines to examine
the regulatory effects of resveratrol and its biotransformed
product, piceatannol, on the expression of PD‑L1. The results
revealed that both dietary stilbenoids, alone or in combination,
copiously increased the expression level of PD‑L1 in some
breast and colorectal cancer cells via HDAC3/p300‑mediated
nuclear factor (NF)-κB signaling. In addition, both stilbenoids
exerted cytotoxic effects on the tumor cells.
Materials and methods
Reagents. Resveratrol, piceatannol, resminostat, entinostat,
mocetinostat, vorinostat, curcumin, garcinol, anacardic acid
and Tip60i were purchased from Selleckchem (Houston,
TX, USA). MB-3 and BMS‑345541 were purchased from
MilliporeSigma (Burlington, MA, USA). Pterostilbene and
myricetin were from LKT Laboratories (St. Paul, MN, USA)
and trimethoxy-resveratrol (trans-3,5,4'-trimethoxystilbene)
was from Cayman Chemical Co. (Ann Arbor, MI, USA).
Stock solutions of the chemicals were prepared based on the
information provided by the manufacturer and maintained
at -20˚C. The antibodies for human PD‑L1 (E1L3N, 13684),
p38 MAPK (D13E1, 8690), NF‑κ B p65 (D14E12, 8242),
γH2AX (20E3, 9718), cleaved caspase 3 (D3E9, 9579), IRF‑1
(D5E4, 8478) and rabbit IgG isotype monoclonal antibody
(DA1E, 5742) conjugated to PE were obtained from Cell
Signaling Technology (Beverly, MA, USA). c‑Myc antibody
(9E10, sc‑40) was obtained from Santa Cruz Biotechnology
Inc. (Santa Cruz, CA, USA). Fetal bovine serum, RPMI-1640,
DMEM, streptomycin and penicillin were from Gibco/Thermo
Fisher Scientific (Waltham, MA, USA). All other chemicals
and solvents were of analytical grade.
Cell culture and treatment. Human BT549 (breast cancer),
BT474 (invasive ductal carcinoma), SKBR3 (breast cancer),
HCT116 (colon cancer), SW480 (colon cancer), HT29 (rectosigmoid adenocarcinoma) and SW620 (colon cancer) cells were
obtained from the American Type Culture Collection (ATCC,
Rockville, MD, USA). Human Cal51 (breast cancer) cells
were from the Leibniz Institute DSMZ-German Collection of

Microorganisms and Cell Cultures (Braunschweig, Germany).
The cells were maintained in RPMI-1640 or DMEM culture
media supplemented with penicillin, streptomycin and
10% heat-inactivated fetal bovine serum according to the
manufacturer's instructions. The cells were split once a week
and the media were changed every 3-4 days.
In all experiments described in this study, parent/parental
or DMSO treated cells all refer to untreated, control cells. For
treated cells, the conditions (dose and treatment duration) and
whether any reagents were used together at specific doses were
as indicated in the figure legends.
Immunohistochemistry. Paraffin-embedded SW620 colon
cancer cells were immunohistochemically stained to evaluate
the protein expression of PD‑L1, c‑Myc, p38 MAPK, γH2AX
and cleaved caspase 3. Following deparaffinization and rehydration, sections of SW620 cells were prepared. The slides
were heated in the Retriever 2000 pressure cooker (Electron
Microscopy Sciences, Hatfield, PA, USA) in Borg buffer pH 9.5
(Biocare Medical, Concord, CA, USA) and cooled to room
temperature. Endogenous peroxidase activity was inactivated
with Peroxidazed 1 (Biocare Medical) for 10 min. Non‑specific
protein interactions were blocked for 10 min with Background
Punisher (Biocare Medical). The sections were incubated
with the primary antibodies, indicated above, at a dilution of
1/200 for 1 h, washed in TBS and incubated with SignalStain
Boost IHC Detection Reagent (Cell Signaling Technology)
for 30 min. Following washes in TBS, immunoreactivity was
visualized by development with 3,3'-diaminobenzidine (DAB+,
Dako, Carpinteria, CA, USA) for 5 min. Immunostained
sections were briefly counterstained with CAT hematoxylin,
washed in tap water, dehydrated in a graded alcohol series,
cleared in xylene and coverslipped with Permount mounting
medium (Fisher Scientific Co. L.L.C., Pittsburgh, PA, USA).
Flow cytometric analysis for the surface expression of
PD‑L1. The cells were harvested and fixed in 4% paraformaldehyde for 10 min. The cells were then rinsed twice with
phosphate-buffered saline (PBS) before a 30‑min staining
was performed to prepare the samples for flow cytometry
using a rabbit anti‑human PD‑L1 monoclonal antibody
(E1L3N) conjugated to phycoerythrin (PE). As controls, cell
samples were also stained for 30 min using rabbit IgG isotype
monoclonal antibody (DA1E) conjugated to PE. Following
labeling with antibody, the cells were rinsed twice with PBS
and re‑suspended with PBS. The data shown as the geometric
means from n=3-4 independent experiments were acquired on
a DB LSR Fortessa X-20, and analyzed with FlowJo version 10
software (BD Biosciences, San Jose, CA, USA).
PD‑L1 mRNA analyses using the Cancer Cell Line Encyclopedia
(CCLE) database. The basal PD‑L1 mRNA expression levels
shown in Fig. 2B, presented as transcript per million (TPM)
were obtained from a public Cancer Cell Line Encyclopedia
(CCLE, https://portals.broadinstitute.org/ccle/home) database
for cancer cell lines tested.
NF‑κB reporter assay. The A549-Dual cells purchased from
InvivoGen (San Diego, CA, USA) were used. These are derivatives of the A549 human lung carcinoma cells containing the
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stable integration of two inducible reporter constructs. The
constructs allow for the co-expression of a secreted embryonic alkaline phosphatase (SEAP) reporter gene under the
control of the IFN-β minimal promoter fused 5 five NF‑κ B
binding sites, and, a Lucia luciferase gene encoding a secreted
luciferase whose transcription is driven by an ISG54 promoter
fused to 5 IFN‑stimulated response elements. The cells were
treated for the specified amount of time (8, 24 and 48 h) with
resveratrol or piceatannol, each at 100 µM or combined, each
at 50 µM (referred to as combo-100) to yield a concentration
of 100 µM and the secreted alkaline phosphatase and Lucia
luciferase in the supernatant of the control and treated cells
were detected using the Quanti‑Blue reagent from InvivoGen.
The results were scored by the fluorescence intensity on
a Perkin Elmer EnSpire set at a wavelength of 650 nm
(PerkinElmer Inc., Shelton, CT, USA). To determine the role of
NF‑κ B in mediating the induction of PD‑L1, the IKK inhibitor,
BMS‑345541, was administered for 24 h in vitro prior to exposure to the combination of piceatannol and resveratrol, each at
50 µM to yield a concentration of 100 µM, for a further 48 h.
BMS‑345541 was added at increasing concentrations (1, 4 and
8 µM), while the dose of the combination was kept constant.
Cell cycle/apoptosis analysis. The cells were harvested and
washed with PBS then re‑suspended in cold 1% formaldehyde
in PBS solution for 15 min at 4˚C. The cells were washed
twice in PBS and re‑suspended in ice-cold 70% ethanol and
stored at -20˚C for 2 h prior to analysis. Prior to fluorescence
measurement the cells were stained with 4',6-diamidine2'-phenylindole dihydrochloride (DAPI). The intensity of blue
fluorescence emission of DAPI stained DNA, excited with the
UV laser (355 nm) was measured, recorded and analyzed on
a MoFlo flow cytometer (Beckman Coulter Life Sciences,
Indianapolis IN, USA) using Kaluza fluorescence intensity
analysis software (48). Experiments were repeated and representative data are presented.
Statistical analysis. All data are presented as the mean ±
the standard error of the mean. A Student's t-test or two-way
ANOVA with Bonferroni correction were performed to determine statistical significance between frequencies or mean
fluorescence intensities of assessed cell populations using
GraphPad Prism 6 (GraphPad Software). Statistical significance of results was as indicated in each figure.
Results
PD‑L1 expression is increased by dietary stilbenoids, resvera‑
trol and/or piceatannol in breast and colorectal cancer cells.
We first assessed any alterations in PD‑L1 levels using the Cal51
breast cancer and HCT116 colon cancer cells treated with stilbenoids, specifically, resveratrol, piceatannol, pterostilbene and
3,5,4'-trimethoxystilbene, for comparison with the flavonoid,
myricetin (the chemical structures of the compounds are shown
in Fig. 1A). The surface expression of PD‑L1 in the control
(DMSO‑treated, also referred to as parent/parental cells) and
treated Cal51 and HCT116 cells was assayed by flow cytometry.
Resveratrol significantly increased the expression of PD‑L1 in
the Cal51 cells, while treatment with piceatannol resulted in a
marked increase in the PD‑L1 level in HCT116 cells (Fig. 1B).

Figure 1. Effects of dietary polyphenols on programmed cell death ligand 1
(PD‑L1) expression in human breast and colon cancer cells. (A) Chemical
structure of each of the polyphenols tested. (B) The Cal51 human breast
cancer cell line and HCT116 colon cancer cell line, were cultured in vitro
and treated with increasing concentrations of 5 polyphenols for 48 h, respectively, namely resveratrol (Res), piceatannol (Pic), pterostilbene (PTS),
trimethylstilbene (TriMRes) and myricetin. Following treatment, the cells
were harvested and stained for the surface expression of PD‑L1 by flow
cytometry. The geometric mean of mean fluorescent intensity (MFI) of
phytoerythrin (PE) area was used as the readout of PD‑L1. The levels of
PD‑L1 were converted to a bar graph to represent the respective changes in
PD‑L1 expression following treatment. The parental condition (also referred
to as DMSO‑treated, or control cells). Statistical difference reflects the comparison of treated samples to the parental condition. The data shown were
from n=3 independent experiments. *P<0.05.

To determine whether the upregulation of PD‑L1 by
resveratrol and piceatannol was broadly or uniquely observed
in specific breast or colon cancer cell lines, we assayed any
alterations in PD‑L1 expression using a panel of breast (Cal51,
BT549, BT474 and SKBR3) and colorectal (HCT116, SW480,
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Figure 2. Effects of resveratrol and piceatannol on programmed cell death ligand 1 (PD‑L1) expression in human breast and colon cancer cells. (A) A panel of
4 breast (Cal51, BT549, BT474 and SKBR3) and colorectal (HCT116, SW480, HT29 and SW620) cancer cell lines were incubated with increasing concentrations of resveratrol or piceatannol, as single agents or in combination for 48 h. Following treatment, the cells were harvested and stained and quantified for
PD‑L1-PE surface expression by flow cytometry. The induction of PD‑L1 expression was based on comparison to a DMSO‑treated sample (control used
throughout all experiments), and to isotype control staining. The geometric mean of MFI of PE area was used as the PD‑L1 readout. The levels of PD‑L1
from n=3 experiments were converted to a bar graph to represent the respective changes in PD‑L1 expression following treatment. The parental condition
represents the untreated control. The statistical difference reflects comparison of treated samples to parental condition. (B) RNA‑seq analysis of constitutive
mRNA expression of PD‑L1 in panel of breast and colon cancer cells. Basal PD‑L1 mRNA levels, shown as transcript per million (TPM) were obtained from a
public Cancer Cell Line Encyclopedia (CCLE) database and ranked from low to high according to the relative TPM expression by most of the breast and colon
cancer cell lines tested in (A) https://portals.broadinstitute.org/ccle/home. The asterisks apply to comparisons made among treated samples: *P<0.05, **P<0.01,
***
P<0.001. In addition, the ‘x’ symbol refers to comparisons made between the untreated, control sample with the treated sample: xP<0.05 (treated vs. control).

HT29 and SW620) cancer cell lines. In addition, we also
determined whether the synergistic upregulation of PD‑L1
may result from treatment with the two stilbenoids. The differential increase in PD‑L1 expression induced by resveratrol
or piceatannol was observed in 2/4 breast and 3/4 colorectal
cancer cell lines treated with either of the stilbenoids as a
single agent (Fig. 2A). The combination of resveratrol and
piceatannol acted synergistically; 50 µM each of resveratrol
and piceatannol combined and referred to as ‘combo-100’
resulted in significantly greater induction of PD‑L1 expression; specifically, ≥4.5-fold in the Cal51 and ≥3.5-fold in the
SW620 cells than 50 µM of either stilbenoid added alone
(Fig. 2A). Gene expression analyses frequently reveal that the
relative abundance of mRNA is only weakly or even inversely
associated with the level of protein expression (49-51). Thus,
in this study, to determine whether the differential expression
level of endogenous PD‑L1 mRNA might contribute to the
observed induction of PD‑L1 by resveratrol and piceatannol
in these two cell lines, relative to the panel of the other studied
cell lines with the same cancer type grouping, the basal PD‑L1

mRNA expression levels, shown as TPM were obtained from
a public Cancer Cell Line Encyclopedia (CCLE, https://
portals.broadinstitute.org/ccle/home) database for cancer cell
lines tested. In the breast cancer cell lines, the endogenous
level of PD‑L1 mRNA ranked as follows: Cal51 ≤ BT474
< SKBR3 ≤ BT549 (Fig. 2B); however, the induction of PD‑L1
by co-treatment with resveratrol and piceatannol yielded the
opposite result: Cal51 (~7-fold) ≥ BT474 (~ 4-fold) > SKBR3
(~2-fold) ≥ BT549 (~2-fold) (Fig. 2A). A similar trend was also
observed in the colorectal cancer cells; namely, the endogenous
PD‑L1 mRNA ranking was as follows: SW620 ≤ HCT116
< HT29 ≤ SW480 (Fig. 2B), whereas the relative induction of
PD‑L1 decreased from high to low as follows: SW620 (~4-fold)
> HCT116 (~3-fold) > SW480 (~3-fold) > HT29 (~1.5-fold)
(Fig. 2A). These results suggest that tumors with a low endogenous mRNA level of PD‑L1 are more likely to be affected by
resveratrol and/or piceatannol, alone or in combination.
NF‑ κ B mediates the upregulation of PD‑L1 induced by
resveratrol and/or piceatannol. IFN-γ is known to induce
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Figure 3. Control of nuclear factor (NF)-κ B-mediated programmed cell death ligand 1 (PD‑L1) expression by resveratrol and piceatannol. (A) A549 dual
reporter cells were used to assay the activation of NF‑κ B following treatment with resveratrol or piceatannol, each at 100 µM or combined, each at 50 µM
(referred to as combo-100) to yield a concentration of 100 µM. Resveratrol as a single agent resulted in an optimal early time activation of NF‑κ B, while
piceatannol alone decreased NF‑κ B signaling at 8 h and followed by a progressive increases at 24 and 48 h, respectively. When used in combination, the
two stilbenoids led to a marked increase in NF‑κ B signaling over the tested duration of 48 h. The parental condition represents the untreated control. The
data shown are from 1 experiment. (B) Immunohistochemistry of the subcellular localization of NF‑κ B p65 subunit in SW620 colon cancer cells treated
with a combination of piceatannol and resveratrol, each at 50 µM to yield a concentration of 100 µM vs. the untreated cells. The analysis showed that p65
translocated from the cytoplasm to the nucleus by the combined use of the stilbenoids, indicating the activation of NF‑κ B signaling. Images were captured at
x20 magnification and cropped to show the field of cells representative of the effect of treatment. The results are representative of 5 sections from 1 experiment.
We did not quantify the percentage of cells in which translocation occurred in these samples. The parental condition represents the control. The image in the
inset represents a high magnification image of the cells in the field of view. (C) BMS‑345541, an inhibitor of IKK, was administered for 24 h in vitro prior to
exposure to the combination of piceatannol and resveratrol, each at 50 µM to yield a concentration of 100 µM, for a further 48 h. BMS‑345541 was added at
increasing concentrations (1, 4 and 8 µM) while the dose of the combination was kept constant. Following treatment, the cells were harvested and stained for
PD‑L1 expression by flow cytometry. The geometric mean of the mean fluorescent intensity (MFI) of the phytoerythrin (PE) area was used as the readout for
PD‑L1 expression. The parental condition represents the untreated control. The results are representative of 3 experiments.

PD‑L1 expression by upregulating its transcription through
the activation of interferon regulatory transcription factor
(IRF‑1) (52,53). Thus, in this study, we investigated whether
the same mechanism may contribute to the resveratroland/or piceatannol-mediated induction of PD‑L1 expression.
The results of immunohistochemistry revealed no change in
IRF‑1 expression in the SW620 cells treated for 48 h with
‘combo-100’ compared to the control (data not shown). Since
the NF‑κ B consensus sequence is also present in the PD‑L1
gene promoter (52,53), and NF‑κ B plays a major role in the
transcription of PD‑L1 by IFN-γ (54-56), in this study, we
examined whether the induction of PD‑L1 by resveratrol and/or

piceatannol was due to the activation of NF‑κ B. The A549
cells co-expressing the SEAP reporter gene and Lucia luciferase gene were used to investigate the association between
NF‑κ B activity and the PD‑L1 expression levels following
treatment with the two stilbenoids, alone or combination. In
this dual reporter assay, the secreted SEAP and Lucia luciferase in the culture supernatant were separately measured to
provide a quantitative readout of the transcriptional impact of
NF‑κ B and the IFN signaling pathways. The time-dependent
(≥24 h) and synergistic induction of NF‑ κ B expression
induced by piceatannol alone and by combined treatment with
resveratrol was observed (Fig. 3A). In response to stimuli, the
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Figure 4. Effects of histone deacetylase inhibitors (HDACis) and histone acetyltransferase inhibitors (HATis) on the induction of programmed cell death
ligand 1 (PD‑L1) expression. (A) The SW620 colon cancer cell line was treated in vitro with different classes of HDACis at various concentrations for 72 h.
Following treatment, the cells were harvested and stained for PD‑L1 expression by flow cytometry. The results were quantified using the geometric mean of
the mean fluorescent intensity (MFI) of the phytoerythrin (PE) area as the readout for the expression of PD‑L1. (B) The same cancer cell line, SW620, was
treated with a known class of HATis listed, for 72 h and PD‑L1 expression was analyzed and quantified. ‘Combo’ indicates treatment with both resveratrol and
piceatannol each at 60 µM for 48 h. The parental condition represents the untreated control. The data shown are from 1 experiment.

inhibitory protein Iκ B is degraded, which leads to the release/
translocation of heterodimer p65/p50 from the cytoplasm to
the nucleus (57,58). Therefore, the activation of NF‑κ B by the
combined stilbenoids was examined in the SW620 cells by
immunohistochemistry to analyze changes in the localization
of p65; 48 h of exposure to ‘combo-100’ resulted in an increase
in the translocation and nuclear accumulation of p65, as shown
in Fig. 3B (inset).
The small molecule, BMS‑345541, is an IKK kinase
inhibitor (59) that prevents Iκ B phosphorylation, to effectively
suppress the translocation of NF‑κ B into the nucleus for
participation in transcriptional activation of NF‑κ B-responsive
genes (57,58). Thus, in this study, we then examined whether
the stilbenoid-induced PD‑L1 expression can be blocked by
BMS‑345541. In SW620 cells, the induction of PD‑L1 by
‘combo-100’ was inhibited by 48% with 1 µM BMS‑345541
(Fig. 3C). Furthermore, a dose-dependent inhibition was
observed with the 1, 4 and 8 µM of IKK inhibitor concentration range (Fig. 3C). These results, showing that the inhibition
of IKK significantly decreased PD‑L1 expression in SW620
cells suggest that NF‑κ B activation is involved in the induction

of PD‑L1 expression by resveratrol or piceatannol either alone,
or in combination.
Histone deacetylase inhibitors (HDACis) and histone acet‑
yltransferase inhibitors (HATis) modulate the induction of
PD‑L1 expression induced by the combination of resveratrol
and piceatannol. The expression of PD‑L1 can be regulated via
histone acetylation/deacetylation (60,61) and resveratrol is an
activator of HDAC (62). To investigate whether the induction
of PD‑L1 by the combination of resveratrol and piceatannol
is blocked by inhibitors of HDAC or HAT, HDACis (vorinostat, mocetinostat, resminostat and entinostat) and HATis
(curcumin, garcinol, anacardic acid, MB-3 and Tip60i) were
used to assess their effects on the modulation of PD‑L1 by
the combined use of the stilbenoids. The cells were pre-treated
for 48 h with individual HDACis/HATis alone or in combination with 60 µM of either of the stilbenoids, followed by the
flow cytometric analysis of PD‑L1 expression. The addition
of HDACis or HATis alone did not affect PD‑L1 expression
compared to the untreated controls (Fig. 4). When the SW620
cells were pre-treated with histone modification inhibitors,
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Figure 5. Effects of histone deacetylase inhibitors (HDACis) and histone acetyltransferase inhibitors (HATis) on the induction of programmed cell death
ligand 1 (PD‑L1) expression by a combination of resveratrol and piceatannol. (A) The SW620 colon cancer cell line was treated in vitro with increasing concentrations of HDACis for 24 h prior to exposure to a combination of resveratrol and piceatannol, each at 60 µM, for an additional 48 h. Following treatment,
the cells were harvested and stained for PD‑L1 expression by flow cytometry. The geometric mean of the mean fluorescent intensity (MFI) of the phytoerythrin
(PE) area was used as the readout for PD‑L1 expression. The high dose of entinostat and resminostat significantly reduced expression of PD‑L1. (B) The SW620
cells were treated with listed HATis, for 24 h prior to exposure to the combined treatment as described in Fig. 3A. The analysis and quantification of PD‑L1
were identical to those shown in Fig. 3A. ‘Combo’ indicates treatment with both resveratrol and piceatannol each at 60 µM for 48 h. The parental condition
represents the untreated control.

the ability of the stilbenoids to induce PD‑L1 was markedly
reduced by two HDACis (5 µM of resminostat and entinostat)
and also by the HATi, anacardic acid (1 µM) (Fig. 5). These
results demonstrated that histone modification inhibitors can
suppress the induction of PD‑L1 expression by stilbenoids. The
data are consistent with the interpretation that the upregulation
of PD‑L1 by stilbenoids involves transcriptional control.
Induction of apoptotic and cell cycle changes by the combined
use of resveratrol and piceatannol. The upregulation of PD‑L1
may allow cancers to evade the host immune system and
acquire resistance to anticancer drugs. Having demonstrated
that the upregulation of PD‑L1 expression by stilbenoids in
the SW620 colon cancer cells, we then investigated whether
stilbenoids affect the survival status of cells by analyzing two
biomarkers related to apoptosis, namely, the expression of the
DNA damage indicator γH2AX, and that of cleaved caspase 3.
In addition, markers associated with cell survival, p38-MAPK

and c‑Myc, were also assessed using immunohistochemistry.
Treatment of the SW620 cells for 48 h with ‘combo-100’ resveratrol and piceatannol increased the expression of γH2AX and
that of cleaved caspase 3, and downregulated the p38-MAPK
and c‑Myc levels (Fig. 6A). The induction of γH2AX is characteristic of DNA fragmentation and damage during apoptosis,
and thus supports the interpretation that exposure to resveratrol and/or piceatannol causes DNA damage and apoptosis via
the activation of caspase 3. We then assessed whether treatment with the stilbenoids altered cell cycle distribution by flow
cytometric analysis. An increase in the percentage of cells in
the S phase of the cell cycle, from 19 to ~30%, a distinct reduction in the proportion of G1 phase cells (from 66 to ~30%),
and a marked decrease in the percentage of G2M phase cells,
from 12 to ~3% were observed. There was also an increase in
the percentage of cells with fractional DNA content (‘sub‑G1
cells’), an indication of apoptosis from 2.85% in the control
cells to 31.84, 35.08 and 36.55% in the cells treated with
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Figure 6. Effects of resveratrol and/or piceatannol on the cell survival and cell cycle status. (A) Immunohistochemical staining of SW620 parental cells, top
row, and cells treated with the combination of resveratrol and piceatannol, each at a concentration of 50 µM, are shown on the bottom row. Cells from both
conditions were stained with antibodies against γH2AX, cleaved caspase 3, p38 MAPK and c‑Myc, as described in the Materials and methods. Images were
captured at x20 magnification and cropped to show the field of cells representative of the effect of treatment. (B) Flow cytometric analysis of the changes on
cell cycle status and apoptotic index of SW620 cells. The percentage of cells in particular phases of the cell cycle identified by their DNA content is indicated.
The data are shown from a single representative experiment.

Figure 7. Flow cytometric analysis of the changes in cell cycle status and the apoptotic index of Cal51 and SW620 cells. (A) Untreated cells. (B) Cells treated
with 10 µM resveratrol, 48 h. (C) Cells treated with 10 µM piceatannol, 48 h. (D) Cells treated with 10 µM of resveratrol plus 10 µM piceatannol, 48 h. The
percentage of apoptotic cells (Ap) identified by fractional DNA content, sub‑G1 cells is shown in each panel (thick arrows). The percentage of cells in particular
phases of the cell cycle identified by their DNA content, are as shown by the thin arrows in the top panel (Ca151 cells) and the bottom panel (SW620 cells). The
data shown are representative of two experiments.

INTERNATIONAL JOURNAL OF ONCOLOGY 53: 1469-1480, 2018

50 µM resveratrol, 50 µM piceatannol or 50 µM of these two
compounds for 48 h, respectively (Fig. 6B). We also examined
and determined that low-dose (10 µM) resveratrol and/or
piceatannol did not induce PD‑L1 expression, whereas the
analysis of cell cycle phase distribution changes using Cal51
and SW620 cell cultures treated for 48 h revealed an apparent
increase in the proportion of S‑phase cells concomitant with
the reduction of G2M-phase cells in cultures treated with
resveratrol alone, and to an even greater extent following
treatment with both stilbenoids (Fig. 7). In addition, the
combination of resveratrol and piceatannol induced apoptosis
in both cell types to a much greater degree than each of them
alone, as demonstrated by an increase in the percentage of
cells with fractional DNA content (‘sub‑G1 cells’), an indication of apoptosis (compare Fig. 7A with Fig. 7B-D) (48,63,64).
Taken together, our findings indicate that stilbenoids not only
increase PD‑L1 expression, but may also induce DNA damage,
leading to increased cell death in tumor cells, such as SW620
colon cancer cells.
Discussion
An association has been observed between a decrease in T-cell
proliferation and an increase in apoptosis and tumor immune
evasion, with an increase in the expression of T-cell inhibitory
protein PD‑L1 on cancer cells (2,3), providing the impetus for
understanding the control of PD‑L1 expression using cancer
cells as a model. In this study, we examined the hypothesis that
dietary stilbenoids may act as modulators of PD‑L1 expression in tumor cells. We focused on the effects of resveratrol,
a grape-derived polyphenol that has shown chemopreventive
effects in various cancer types (33-42), and its hydroxylated
derivative, piceatannol. Questions raised and addressed in
this study included whether: i) Structurally-modified stilbenoids have the same ability to modulate PD‑L1 expression;
ii) the effects of stilbenoids on PD‑L1 expression can apply
to different cancer types; iii) signaling pathways that control
the stilbenoid-induced PD‑L1 expression are effected; and
iv) histone modification inhibitors (HDACis and HATis) block
stilbenoid-induced PD‑L1 expression.
Stilbenoids in general exert beneficial effects on human
health (65). It has been reported that the 4'-hydroxy group of
resveratrol is essential for its bioactivity (66). In this study, we
used breast and colorectal cancer cells to compare the modulatory
effects of stilbenoids on PD‑L1 expression, namely, piceatannol
(3',4',3,5-trans-trihydroxystilbene), 3,5,4'-trimethoxystilbene,
and pterostilbene (3,5-dimethoxy-4'-hydroxy-E‑stilbene), with
resveratrol (3,5,4'-trans-trihydroxystilbene) and myricetin, a
naturally occurring flavonoid present in abundance in edible
foods (67). The results presented in Figs. 1 and 2 demonstrate
that the hydroxyl, but not methoxy groups on stilbenoids are
important for the induction of PD‑L1. However, no increase in
PD‑L1 expression was evident in the cells treated with myricetin
(3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-4-chromenone),
a flavonoid that contains 6 hydroxyl groups (Fig. 1). These
results suggest that the 3,5-dihydroxy-trans‑stilbene structure
is required for the induction of PD‑L1 in the cells used.
The expression level PD‑L1 of was significantly increased
in the breast and colon cancer cells treated with resveratrol
and piceatannol, both as a single agent and when used in
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combination (Figs. 1 and 2). Moreover, PD‑L1 expression
was synergistically upregulated 4.5-fold in the Cal51 breast
cancer and ≥3.5-fold in the SW620 colon cancer cells by the
combined use of resveratrol and piceatannol (Fig. 2A). Of note,
both cancer cells express low basal levels of PD‑L1 mRNA
expression (Fig. 2B). Since, as noted, a positive response and
improved clinical outcome to anti‑PD‑L1 blockade therapy are
best observed in patients with PD‑L1-positive tumors (presumably reflecting a high expression of PD‑L1), we surmise that
agents capable of upregulating PD‑L1 expression in tumor
cells expressing low PD‑L1 can sensitize such cancer cells for
an improved response to PD‑L1 blockade. As a corollary, we
also hypothesized that the combined use of resveratrol and
piceatannol co-administered with anti‑PD‑L1 immunotherapy
may exhibit clinical benefits in cancer patients with no-orlow-PD‑L1 tumors. Whether the efficacy to PD‑L1 blockade
may be enhanced by the combined intake of resveratrol and/
or piceatannol, concomitantly or sequentially, remains to be
verified.
This study also provides evidence showing that the resveratrol- and piceatannol-mediated upregulation of PD‑L1 requires
the activation of NF‑κ B (Fig. 3). In the SW620 cells, we showed
that the induction of PD‑L1 expression induced by resveratrol/
piceatannol was attenuated by the IKK inhibitor, BMS 345541
(Fig. 3C). It has been previously demonstrated that the duration and function of nuclear NF‑κ B is regulated by reversible
acetylation/deacetylation (68), and that NF‑κ B transcriptional
response is controlled by the HDAC3-mediated deacetylation
of RelA acting as an intranuclear molecular switch for turning
‘on-off’ the NF‑κ B response (68); we therefore examined
whether histone modification inhibitors affect the resveratrol/
piceatannol-mediated transcriptional control of PD‑L1. Our
findings revealed that two HDACis (e.g., resminostat and
entinostat) and one HATi, anacardic acid, effectively blocked
the induction of PD‑L1 expression by resveratrol/piceatannol
(Fig. 5). Both resminostat and entinostat are HDAC3 inhibitors, thus lending support that the HDAC3-mediated NF‑κ B
response plays a role in resveratrol/piceatannol-induced PD‑L1
expression. The suppression of PD‑L1 induction by resveratrol
using anacardic acid is in accordance with the described effect
of anacardic acid as a HATi for p300 and p300/CBP and data
reporting that resveratrol is a p300 activator (69,70). These
results indicate that the expression of PD‑L1 is regulated by
the mechanism of histone acetylation/deacetylation and that
resveratrol/piceatannol induces PD‑L1 expression through
HDAC3/p300‑mediated NF‑κ B control.
It should be mentioned that the upregulation of PD‑L1
by resveratrol or piceatannol occur at doses not achievable
physiologically and may exceed pharmacologically relevant
concentrations (26,71). Conceivably, the effective dose could
also be modulated by factors present locally at the site of
responsive cells/tumors (e.g., different hormones, cytokines,
products of cell metabolism or variable oxygen tension)
and thus may additionally affect sensitivity of PD‑1/PD‑L1
checkpoint to these compounds, perhaps amplifying their
potential anticancer effect. It should also be noted that the
doses used in the present experiments were based on titration
studies (data not shown), and that the effectiveness of single or
combined agents on the induction of PD‑L1 in each cell line
is above IC50. It would be of interest to determine what might
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account for the variations observed in dosage dependence in
different cell lines. Since the induction of PD‑L1 expression by
resveratrol and piceatannol are mediated through the NF‑κ B
signaling pathway; the different dose-dependent responses
and the upregulation of PD‑L1 by resveratrol and piceatannol
may be due to the variation in the endogenous level of NF‑κ B
components, vis-à-vis, NF‑κ B1 (p105), NF‑κ B2 (p65), CHUK
(IKK-α), IKBKB (IKK-β) and IKBKG (IKK-γ), in each of the
cell lines tested. In RNA‑seq analyses, we found that Cal51
and SW620, both with a low endogenous level of PD‑L1
expression, expressed high levels NF‑κ B2 (p65) and CHUK
(IKK-α) compared to cancer cell lines from same anatomical
origin showing high PD‑L1 expression (data not shown).
Thus, it is tempting to propose that response in the induction
of PD‑L1 by stilbenoids in different cell lines from identical
cancer types may be attributed to the level of expression of
NF‑κ B2 (p65) and CHUK (IKK- α). Currently, experiments
are underway to further test and confirm our hypothesis.
Another result of note in this study is that the SW620
cells exposed to a high dose of both stilbenoids were partially
restricted in cell cycle transition in the G2/M phase and display
evidence of apoptosis (Fig. 6). Furthermore, the accumulation
of cells in the S phase of the cell cycle may also be associated
with an increase in their expression of PD‑L1. This suggests
that resveratrol and piceatannol affect cancer cells by a dual
mechanism: i) The induction of PD‑L1 that sensitizes tumor
cells for recognition by anti‑PD‑L1 antibodies; an effect that
could diminish cancer cell evasion from immune surveillance; and ii) the direct induction of cell cycle arrest, increase
in DNA damage and cancer cell destruction via induction of
apoptosis.
Since cancer patients expressing tumors positive for PD‑L1,
a negative T-cell regulatory molecule, demonstrate efficacy
to anti‑PD‑L1 blockade therapy with an improved clinical
outcome, one might surmise that low PD‑L1-expressing tumors
may be sensitized and may display an improved responsiveness to PD‑L1 blockade therapy using dietary agents. The cell
culture experiments used in this study may be considered as a
model for testing whether the sensitivity and responsiveness of
tumor cells to PD‑L1 targeted therapy can be augmented by
priming with or co-exposure to stilbenoids, such as resveratrol
and/or piceatannol. The hypothesis raised is as follows: The
upregulation of membrane-associated PD‑L1 in low PD‑L1expressing tumor cells is a ‘find-me’ approach for targeting by
immune checkpoint inhibitors to potentially improve the efficacy of anti‑PD‑L1 blockade therapy via stilbenoids. Indeed,
we believe that the elevation of PD‑L1 expression, as we have
demonstrated in this study using pharmacological doses of
the stilbenoids, resveratrol and piceatannol, may underlie the
unresolved challenge in that the positive response to immune
checkpoint blockade therapy in 19-31% of treated individuals
is a limited to number of clinical indications, typically in
patients whose tumors express elevated-PD‑L1, which we
stated explicitly in the Introduction. Thus, while on teleological
grounds, the upregulation of PD‑L1 by polyphenols in cancer
could promote disease progression, we offer the consideration
that the observed stilbenoid-induced PD‑L1 increase be viewed
from the hypothesis that agents capable of upregulating PD‑L1
expression in tumor cells could sensitize cancer cells for an
improved clinical response to PD‑L1 immune checkpoint

blockade therapy. Testing these aspects would constitute a
novel approach to confirm our hypothesis. These possibilities
are under further investigative considerations in our laboratory. Studies are also planned to explore whether stilbenoids
may impact host immune response, for example, by affecting
PD‑1 expression in PD‑1-expressing Jurkat T-cells.
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